FDA Drug Safety Advisory Cmte. Adds Harvard's Platt Ahead Of COX-2 Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Platt, who joined FDA's Drug Safety & Risk Management Advisory Committee in July 2004, is a member of the national steering committee for AHRQ's Centers for Education & Research in Therapeutics. His research at Harvard centers on using health plan data to improve drug safety and assess drug efficacy.